This study aimed to evaluate cyclophosphamide contamination in community pharmacies, investigate patient-mediated transfer and indirect risks to the public, and examine the association between the use of hospital closed system transfer devices (CSTDs) and this contamination.
Methods
Wipe samples from patient counselling counters at 24 community pharmacies near 10 hospitals were analysed for cyclophosphamide contamination using liquid chromatography-mass spectrometry. A questionnaire survey was conducted to assess CSTD use and cleaning practices.
Results
Contamination was detected in 5/24 pharmacies (20.8%; median level: 0.7 ng/625 cm2). The overall median across the 24 pharmacies was below the limit of quantification, which does not necessarily indicate absence of contamination. Moreover, four of the five pharmacies with contamination did not have cyclophosphamide in stock during the sampling period. Contamination was observed irrespective of hospital CSTD use or the pharmacy’s handling of cyclophosphamide.
Conclusions
Cyclophosphamide contamination detection on patient counselling counters in community pharmacies may be a result of patient-mediated transfer. However, alternative sources within pharmacies, such as inventory, packaging, and local handling, cannot be ruled out. Contamination was detected in settings with and without hospital CSTD use, indicating that CSTDs address handling-related contamination but do not mitigate patient-mediated pathways.
NIOSH. NIOSH list of hazardous drugs in healthcare settings. https://www.cdc.gov/niosh/docs/2025-103/pdfs/2025-103.pdf?id=10.26616/NIOSHPUB2025103 (2024), 2024, accessed 6 August 2025.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42: this publication represents the views and expert opinions of an IARC ad-hoc working group on the evaluation of carcinogenic risks to humans, which met in Lyon, 10-18 march 1987. Lyon: World Health Organization, International Agency for Research on Cancer, 1987.
11.
ConnorTHShultsMFraserMP. Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37°C using a desiccator technique. Mutat Res2000; 470: 85–92.
12.
CrulMHilhorstSBreukelsO, et al.Occupational exposure of pharmacy technicians and cleaning staff to cytotoxic drugs in Dutch hospitals. J Occup Environ Hyg2020; 17: 343–352.
13.
BeigzadehZGolbabaeiFOmidiF, et al.Comparative analysis of dermal and inhalation exposures to antineoplastic drugs among workers in the workplaces: a systematic review. BMC Public Health2025; 25: 1800.
14.
KorczowskaECrulMTuerkJ, et al.Environmental contamination with cytotoxic drugs in 15 hospitals from 11 European Countries—Results of the MASHA project. Eur J Oncol Pharm2020; 3: e24.
15.
YukiMSekineSTakaseK, et al.Exposure of family members to antineoplastic drugs via excreta of treated cancer patients. J Oncol Pharm Pract2013; 19: 208–217.
16.
BöhlandtASverdelYSchierlR. Antineoplastic drug residues inside homes of chemotherapy patients. Int J Hyg Environ Health2017; 220: 757–765.
17.
TanigawaHHiroharaMMarutaniY, et al.Duration of sweat cyclophosphamide excretion in patients undergoing a conditioning regimen of high-dose cyclophosphamide for hematopoietic stem-cell transplantation. J Oncol Pharm Pract2023; 29: 619–625.
18.
MiyazawaMYamashitaRIchinoheY, et al.Cyclophosphamide exposure via sweat of patients receiving CHOP therapy. J Oncol Pharm Pract2023; 29: 1646–1651.
19.
JumaFRogersHTrounceJ. The kinetics of salivary elimination of cyclophosphamide in man. Br J Clin Pharmacol1979; 8: 455–458.
HerrstedtJClark-SnowRRuhlmannCH, et al.2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open2024; 9: 102195.
22.
IiharaHAbeMWadaM, et al.Japan society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol2023; 29: 873–888.
23.
KibbyT. A review of surface wipe sampling compared to biologic monitoring for occupational exposure to antineoplastic drugs. J Occup Environ Hyg2017; 14(3): 159–174.
24.
MasonHJBlairSSamsC, et al.External contamination of cytotoxic drugs. Ann Occup Hyg2003; 47(7): 613–618.
25.
HedmerMTinnerbergHAxmonA, et al.Environmental and biological monitoring of antineoplastic drugs. Ann Occup Hyg2005; 49(8): 629–637.
26.
Bernabeu-MartínezMARamos MerinoMSantos GagoJM, et al.Guidelines for safe handling of hazardous drugs: a systematic review. PLoS One2018; 13: e0197172.
27.
Hayes-PorterAShayB. Evaluation of a hazardous drug surface contamination surveillance program in a large community hospital. Am J Health Syst Pharm2025; 82: 1006–1012.
28.
TangYCheXWangYL, et al.Evaluation of closed system transfer devices in preventing chemotherapy agents contamination during compounding process-a single and comparative study in China. Front Public Health2022; 10: 827835.
29.
SimonNVasseurMPinturaudM, et al.Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug-compounding unit: a prospective, controlled, parallel study. PLoS One2016; 11: e0159052.
30.
ClarkBASessinkPJ. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents. J Oncol Pharm Pract2013; 19: 99–104.
31.
SessinkPJConnorTHJorgensonJA, et al.Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract2011; 17: 39–48.
32.
GurusamyKSBestLMTanguayC, et al.Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff. Cochrane Database Syst Rev2018; 3: CD012860.
33.
CallEBillBMcLeanC, et al.Hazardous drug contamination of drug preparation devices and staff: a contamination study simulating the use of chemotherapy drugs in a clinical setting. Hosp Pharm2017; 52: 551–558.
34.
MergerDTanguayCLangloisÉ, et al.Environmental contamination with methotrexate in Canadian community pharmacies. J Am Pharm Assoc2013; 53: 423–426.
